Cargando…

Impact of regulatory interventions to restrict the combined use of renin–angiotensin system blockers: A Danish nationwide drug utilisation study

This study aimed to evaluate the impact of the risk minimisation measures issued by the European Medicines Agency in 2014 to restrict the combined use of renin–angiotensin system (RAS) blocking agents in Denmark. Data from the Danish National Prescription Registry covering all medications dispensed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sindahl, Per, Ofori‐Asenso, Richard, Hallgreen, Christine Erikstrup, Kemp, Kaare, Gardarsdottir, Helga, De Bruin, Marie Louise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293443/ https://www.ncbi.nlm.nih.gov/pubmed/34519065 http://dx.doi.org/10.1111/bcp.15080

Ejemplares similares

Are Further Interventions Needed to Prevent and Manage Hospital-Acquired Hyponatraemia? A Nationwide Cross-Sectional Survey of IV Fluid Prescribing Practices
por: Sindahl, Per, et al.
Publicado: (2020)

Impact of a Treatment Guide on Intravenous Fluids in Minimising the Risk of Hospital-Acquired Hyponatraemia in Denmark
por: Sindahl, Per, et al.
Publicado: (2023)

Renin–Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study
por: Christiansen, Christian Fynbo, et al.
Publicado: (2020)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges
por: Ofori-Asenso, Richard, et al.
Publicado: (2020)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19
por: Garg, Aakash, et al.
Publicado: (2020)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
por: Siragy, Helmy M
Publicado: (2011)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro
por: Caminhotto, R de O., et al.
Publicado: (2016)

Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2
por: Lévy, Bernard I., et al.
Publicado: (2020)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Impact of renin-angiotensin system inhibitors and beta-blockers on dental implant stability
por: Saravi, Babak, et al.
Publicado: (2021)

Impact of Renin‐Angiotensin System Blockers on Mortality in Veterans Undergoing Cardiac Surgery
por: Antoniak, Derrick T., et al.
Publicado: (2021)

Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension
por: Kuzeytemiz, Mustafa, et al.
Publicado: (2022)

Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
por: Konoshita, Tadashi, et al.
Publicado: (2009)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis
por: Morrow, Richard L, et al.
Publicado: (2022)

Angiotensin II Receptor Blocker Attenuates Intrarenal Renin-Angiotensin-System and Podocyte Injury in Rats with Myocardial Infarction
por: Wen, Zhu-zhi, et al.
Publicado: (2013)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
por: Morishita, Yoshiyuki, et al.
Publicado: (2014)

COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
por: Genet, Bastien, et al.
Publicado: (2020)

Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy
por: Wang, Weidong, et al.
Publicado: (2020)

Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension
por: Wei, Jie, et al.
Publicado: (2019)

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Severe food restriction activates the central renin angiotensin system
por: De Souza, Aline Maria Arlindo, et al.
Publicado: (2020)

The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study
por: Luño, José, et al.
Publicado: (2017)

Implications of renin‐angiotensin‐system blocker discontinuation in acute decompensated heart failure with systolic dysfunction
por: Darden, Douglas, et al.
Publicado: (2019)

Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022)

Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
por: Morales, Daniel R, et al.
Publicado: (2020)

Assessment of Oxidative Stress Markers in Hypertensive Patients under the Use of Renin-Angiotensin-Aldosterone Blockers
por: Vazquez-Agra, Nestor, et al.
Publicado: (2023)

Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade
por: Lin, Chih-Ching, et al.
Publicado: (2017)

Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease
por: Shen, Jian, et al.
Publicado: (2016)

Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia
por: Di Tano, Giuseppe, et al.
Publicado: (2020)

Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence
por: Turgeon, Ricky D., et al.
Publicado: (2020)

Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study
por: Morales, Daniel R., et al.
Publicado: (2020)

Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization
por: Sim, Hui Wen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_09cmte93nipqtpjdlb99g1ahmf